rs750088530
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1PM2PP5
The NM_080605.4(B3GALT6):c.353delA(p.Asp118fs) variant causes a frameshift change. The variant allele was found at a frequency of 0.000011 in 1,269,262 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. D118D) has been classified as Likely benign.
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000011 ( 0 hom. )
Consequence
B3GALT6
NM_080605.4 frameshift
NM_080605.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 3.96
Genes affected
B3GALT6 (HGNC:17978): (beta-1,3-galactosyltransferase 6) The enzyme encoded by this intronless gene is a beta-1,3-galactosyltransferase found in the medial Golgi apparatus, where it catalyzes the transfer of galactose from UDP-galactose to substrates containing a terminal beta-linked galactose moiety. The encoded enzyme has a particular affinity for galactose-beta-1,4-xylose found in the linker region of glycosamines. This enzyme is required for glycosaminoglycan synthesis. [provided by RefSeq, Jun 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 11 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 23 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-1232630-GA-G is Pathogenic according to our data. Variant chr1-1232630-GA-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 60490.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=1, Likely_pathogenic=1}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
B3GALT6 | NM_080605.4 | c.353delA | p.Asp118fs | frameshift_variant | 1/1 | ENST00000379198.5 | NP_542172.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
B3GALT6 | ENST00000379198.5 | c.353delA | p.Asp118fs | frameshift_variant | 1/1 | 6 | NM_080605.4 | ENSP00000368496.2 |
Frequencies
GnomAD3 genomes AF: 0.0000133 AC: 2AN: 150212Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
2
AN:
150212
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000257 AC: 2AN: 77788Hom.: 0 AF XY: 0.0000223 AC XY: 1AN XY: 44860
GnomAD3 exomes
AF:
AC:
2
AN:
77788
Hom.:
AF XY:
AC XY:
1
AN XY:
44860
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000107 AC: 12AN: 1119050Hom.: 0 Cov.: 30 AF XY: 0.0000112 AC XY: 6AN XY: 535372
GnomAD4 exome
AF:
AC:
12
AN:
1119050
Hom.:
Cov.:
30
AF XY:
AC XY:
6
AN XY:
535372
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000133 AC: 2AN: 150212Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 73282
GnomAD4 genome
AF:
AC:
2
AN:
150212
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
73282
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:2Uncertain:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 07, 2023 | Frameshift variant predicted to result in abnormal protein length as the last 212 amino acids are replaced with 159 different amino acids, and other similar variants have been reported in HGMD; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 23664117, 31614862) - |
Ehlers-Danlos syndrome, spondylodysplastic type, 2 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 06, 2013 | - - |
Spondyloepimetaphyseal dysplasia with joint laxity;C3809210:Ehlers-Danlos syndrome, spondylodysplastic type, 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 10, 2022 | This sequence change creates a premature translational stop signal (p.Asp118Alafs*160) in the B3GALT6 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 212 amino acid(s) of the B3GALT6 protein. This variant is present in population databases (rs750088530, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with B3GALT6-related conditions (PMID: 23664117, 31614862). ClinVar contains an entry for this variant (Variation ID: 60490). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at